Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

CG Oncology (CGON) Cash & Equivalents (2023 - 2025)

Historic Cash & Equivalents for CG Oncology (CGON) over the last 3 years, with Q3 2025 value amounting to $45.1 million.

  • CG Oncology's Cash & Equivalents rose 399.44% to $45.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $45.1 million, marking a year-over-year increase of 399.44%. This contributed to the annual value of $257.1 million for FY2024, which is 300994.44% up from last year.
  • CG Oncology's Cash & Equivalents amounted to $45.1 million in Q3 2025, which was up 399.44% from $14.6 million recorded in Q2 2025.
  • CG Oncology's Cash & Equivalents' 5-year high stood at $257.1 million during Q4 2024, with a 5-year trough of $8.3 million in Q4 2023.
  • Over the past 3 years, CG Oncology's median Cash & Equivalents value was $42.4 million (recorded in 2024), while the average stood at $64.1 million.
  • As far as peak fluctuations go, CG Oncology's Cash & Equivalents soared by 300994.44% in 2024, and later tumbled by 4646.56% in 2025.
  • Quarter analysis of 3 years shows CG Oncology's Cash & Equivalents stood at $8.3 million in 2023, then surged by 3009.94% to $257.1 million in 2024, then tumbled by 82.44% to $45.1 million in 2025.
  • Its Cash & Equivalents was $45.1 million in Q3 2025, compared to $14.6 million in Q2 2025 and $41.5 million in Q1 2025.